Blog

Magenta inks deal with Heidelberg to add new ADCs to its transplant palette – FierceBiotech


FierceBiotech

Magenta inks deal with Heidelberg to add new ADCs to its transplant palette
FierceBiotech
The two companies will combine Magenta's stem cell expertise with Heidelberg's ATAC platform to develop ADCs loaded with a toxin (amanitin) against four undisclosed cellular targets. (rawpixel via Unsplash). Share Facebook Twitter LinkedIn Email Print
Magenta, Heidelberg Pharma Launch Bone Marrow Transplant ADC CollaborationGenetic Engineering & Biotechnology News



all 3 news articles »

2018-03-06 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.